Intravenous nicorandil pretreatment improves myocardial strain and attenuates microvascular obstruction in STEMI patients undergoing primary PCI: a randomized, double-blind, placebo-controlled CMR study

Myocardial strain provides a sensitive and reliable assessment of myocardial function during the acute phase of ST-segment elevation myocardial infarction (STEMI). Nicorandil has been proposed as a cardioprotective agent, but its effects on myocardial strain have not been systematically evaluated. This study aimed to evaluate the effects of nicorandil on myocardial strain and long-term major adverse cardiovascular events (MACE) in STEMI patients. This post hoc, exploratory single-center substudy of the randomized, double-blind, placebo-controlled CLEAN trial included 73 STEMI patients with evaluable CMR data who had been allocated to intravenous nicorandil ( n = 36) or placebo ( n = 37) before primary PCI. Cardiac magnetic resonance (CMR) was performed at a median of 4 (3, 5) days. MACE were recorded over a median follow-up of 42 (36, 46) months. Compared with the control group, the nicorandil group demonstrated significantly improved global longitudinal strain, global circumferential strain, global radial strain, Left atrial (LA) reservoir strain, and LA booster strain ( P < 0.05), while LVEF did not differ significantly ( P = 0.348). Late gadolinium enhancement, microvascular obstruction (MVO) incidence, and caIMR were all significantly lower in the nicorandil group ( P < 0.05). There was no statistically significant difference in MACE-free survival between groups (log-rank P = 0.186). Among STEMI patients with evaluable CMR, intravenous nicorandil pretreatment before primary PCI was associated with more favorable myocardial strain, smaller infarct size, less MVO, and lower caIMR. These exploratory findings require confirmation. ClinicalTrials.gov, NCT04665648; registered on 02 December 2020.

Authors

Institutions

Publication Details

Journal
BMC Cardiovascular Disorders
Published
2026-11-17
DOI
https://doi.org/10.1186/s12872-026-06974-4
Primary Topic
Cardiac Imaging and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intravenous nicorandil pretreatment improves myocardial strain and attenuates microvascular obstruction in STEMI patients undergoing primary PCI: a randomized, double-blind, placebo-controlled CMR study

Yuan Lu, Peng Lu, Yu Yang, Donglin Liu et al.
1 links
BMC Cardiovascular Disorders
Cardiac Imaging and Diagnostics
article

Intravenous nicorandil pretreatment improves myocardial strain and attenuates microvascular obstruction in STEMI patients undergoing primary PCI: a randomized, double-blind, placebo-controlled CMR study

Yuan Lu, Peng Lu, Yu Yang, Donglin Liu, Mingchang Du, Lei Chen, Zhi Li, Wensu Chen, Xue Yang
article en

Abstract

Myocardial strain provides a sensitive and reliable assessment of myocardial function during the acute phase of ST-segment elevation myocardial infarction (STEMI). Nicorandil has been proposed as a cardioprotective agent, but its effects on myocardial strain have not been systematically evaluated. This study aimed to evaluate the effects of nicorandil on myocardial strain and long-term major adverse cardiovascular events (MACE) in STEMI patients. This post hoc, exploratory single-center substudy of the randomized, double-blind, placebo-controlled CLEAN trial included 73 STEMI patients with evaluable CMR data who had been allocated to intravenous nicorandil ( n = 36) or placebo ( n = 37) before primary PCI. Cardiac magnetic resonance (CMR) was performed at a median of 4 (3, 5) days. MACE were recorded over a median follow-up of 42 (36, 46) months. Compared with the control group, the nicorandil group demonstrated significantly improved global longitudinal strain, global circumferential strain, global radial strain, Left atrial (LA) reservoir strain, and LA booster strain ( P < 0.05), while LVEF did not differ significantly ( P = 0.348). Late gadolinium enhancement, microvascular obstruction (MVO) incidence, and caIMR were all significantly lower in the nicorandil group ( P < 0.05). There was no statistically significant difference in MACE-free survival between groups (log-rank P = 0.186). Among STEMI patients with evaluable CMR, intravenous nicorandil pretreatment before primary PCI was associated with more favorable myocardial strain, smaller infarct size, less MVO, and lower caIMR. These exploratory findings require confirmation. ClinicalTrials.gov, NCT04665648; registered on 02 December 2020.

BMC Cardiovascular Disorders
Affiliated Hospital of Xuzhou Medical College (CN)
National Science and Technology Major Project
Good health and well-being
Cardiac Imaging and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon